23.83

2.32% 0.54

After Hours: 23.14 -0.69 -2.90%

Urogen Pharma Ltd (URGN)

Overview News Price History Option Chain Financials Discussions Forecast

Urogen Pharma Ltd stock is traded at $23.83, with a volume of 754.17K. It is up +2.32% in the last 24 hours and up +26.62% over the past month. UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Previous Close:

$23.29

Open:

$23.33

24h Volume:

754.17K

Relative Volume:

0.96

Market Cap:

$1.16B

Revenue:

$109.79M

Net Income/Loss:

$-153.49M

P/E Ratio:

-7.4241

EPS:

-3.2098

Net Cash Flow:

$-172.59M

1W Performance:

-1.20%

1M Performance:

+26.62%

6M Performance:

+23.41%

1Y Performance:

+117.63%

1-Day Range:

$22.99

$23.89

1-Week Range:

$22.68

$24.42

52-Week Range:

$3.42

$30.00

Urogen Pharma Ltd Stock (URGN) Company Profile

Name

Urogen Pharma Ltd

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

972 9 770 7601

Address

9 HA'TA'ASIYA ST, RA'ANANA

Employee

291

Twitter

@UroGenPharma

Next Earnings Date

2026-05-06

Latest SEC Filings

URGN's Discussions on Twitter

Compare URGN vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
URGN Urogen Pharma Ltd	23.83	1.13B	109.79M	-153.49M	-172.59M	-3.2098
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-26	Initiated	Jefferies	Buy
Aug-19-25	Initiated	Piper Sandler	Overweight
Jun-16-25	Upgrade	H.C. Wainwright	Neutral → Buy
May-22-25	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-16-25	Initiated	Scotiabank	Sector Outperform
Feb-19-25	Resumed	Ladenburg Thalmann	Buy
Aug-22-24	Initiated	Guggenheim	Buy
Feb-08-23	Downgrade	Jefferies	Buy → Hold
Apr-27-22	Initiated	Berenberg	Buy
Apr-16-20	Reiterated	H.C. Wainwright	Buy
Apr-13-20	Reiterated	H.C. Wainwright	Buy
Jan-09-20	Initiated	National Securities	Neutral
May-30-19	Initiated	JP Morgan	Neutral
May-29-19	Initiated	Goldman	Neutral
Jan-29-19	Initiated	H.C. Wainwright	Buy
Nov-08-18	Resumed	Jefferies	Buy
Apr-04-18	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-02-18	Initiated	Ladenburg Thalmann	Buy
Nov-15-17	Reiterated	Oppenheimer	Outperform
Nov-15-17	Downgrade	Raymond James	Outperform → Mkt Perform

View All

Urogen Pharma Ltd Stock (URGN) Latest News

11:18 AM

UroGen earnings in focus: Can ZUSDURI drive commercial momentum? - Investing.com

11:18 AM

06:16 AM

UroGen outlines $1B peak revenue goal for ZUSDURI amid accelerated adoption and expanded pipeline - MSN

06:16 AM

02:30 AM

Understanding Momentum Shifts in (URGN) - Stock Traders Daily

02:30 AM

May 02, 2026

Urogen Pharma (URGN) Projected to Post Quarterly Earnings on Wednesday - MarketBeat

May 02, 2026

Apr 30, 2026

UroGen Pharma : 2025 Annual Report - marketscreener.com

Apr 30, 2026

UroGen Pharma (NASDAQ: URGN) seeks approvals on board, equity plan and bylaws - Stock Titan

Apr 30, 2026

Apr 29, 2026

UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026 - ChartMill

Apr 29, 2026

Apr 27, 2026

Urogen Pharma (NASDAQ:URGN) Rating Increased to Strong-Buy at Jefferies Financial Group - MarketBeat

Apr 25, 2026

Apr 24, 2026

HC Wainwright Predicts Urogen Pharma Q3 Earnings - MarketBeat

Apr 24, 2026

Avoiding Lag: Real-Time Signals in (URGN) Movement - Stock Traders Daily

Apr 24, 2026

Apr 23, 2026

URGN Stock Price, Quote & Chart | UROGEN PHARMA LTD (NASDAQ:URGN) - ChartMill

Apr 23, 2026

Apr 22, 2026

UroGen Pharma (URGN) Stock: Trending Up? (Gains) 2026-04-22Certified Trade Ideas - Cổng thông tin điện tử Tỉnh Sơn La

Apr 22, 2026

Apr 21, 2026